Skip to content

The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis

The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02271620
Enrollment
53
Registered
2014-10-22
Start date
2014-01-31
Completion date
2016-04-30
Last updated
2018-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other Allergic Rhinitis

Keywords

1 prevalence, 2 children, 3 local allergic rhinitis

Brief summary

* To determine prevalence of local allergic rhinitis (LAR) * To evaluate clinical characteristic and severity of local allergic rhinitis * To measure changing of tryptase and Specific IgE for Dermatophagoides pteronyssinus (Dp) after nasal allergen provocation test (NAPT)

Detailed description

Children 8-18 years with NAR were recruited. A NAPT with Der p 1 solutions (NAPT-DP) at 200 AU/mL, 600 AU/mL and 2000 AU/mL at 15-minute interval was performed, respectively. The immediate responses to NAPT-DP were assessed using symptoms score, peak nasal inspiratory flow (PNIF) and acoustic rhinometry (ARM). The nasal tryptase and sIgE-DP were measured at baseline, 15 min and 1 h after positive NAPT-DP. Allergic rhinitis (AR) patients were used as positive control.

Interventions

nasal allergen provocation test

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children 8-15 years who were diagnosed with nonallergic rhinitis (NAR) at least 1 year * No respiratory infections in the previous 4 weeks * No following treatment of * systemic corticosteroid 4 weeks * intranasal corticosteroid 2 weeks * oral antihistamine 1 week * leukotriene antagonist 1 week

Exclusion criteria

* Patients with underlying disease: * chronic rhinosinusitis and nasal polyp * immunological disease * chronic renal disease * hepatobiliary disease * cardiovascular disease * cancer * Parental withdraw consent * Patient with uncontrolled asthma, peak expiratory flow rate (PEFR) \< 80% of predicted

Design outcomes

Primary

MeasureTime frameDescription
prevalence of local allergic rhinitis (LAR)1 yearpositive nasal allergen provocation test with Der p1

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026